Skip to main content

Table 1 pCR by adding Oxaliplatin to 5-FU for rectal cancer

From: Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE)

Trial N Regimen pCR rate
STAR-01 705 5-FU vs. 5-FU + Oxaliplatin 16% vs. 16% (p = 0.904)
ACCORD 12 598 Capecitabine vs. CAPOX 13.9% vs. 19.2% (p = 0.09)
NSABP R-04 1608 5-FU vs. 5-FU + Oxaliplatin vs. Capecitabine vs. CAPOX 17.8% vs. 19.5% (p = 0.42)
CAO/ARO/AIO-04 1236 5-FU vs. 5-FU + Oxaliplatin 13% vs. 17% (p = 0.031)
PETACC-6 1094 Capecitabine vs. CAPOX 11.3% vs. 13.3% (p = 0.31)
Dellas et al. 70 CAPOX + Bevacizumab 17.4%
EXPERT-C 165 CAPOX vs CAPOX + Cetuximab 7% vs. 11% (p = 0.714)
  1. pCR pathologic complete response, 5-FU 5-fluorouracil, CAPOX capecitabine with oxaliplatin